REG - Abingdon Health PLC - US CDMO Operations Update

Abingdon HealthAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250901:nRSA3132Xa&default-theme=true

RNS Number : 3132X  Abingdon Health PLC  01 September 2025

 

Abingdon Health plc

("Abingdon Health", the "Group" or the "Company")

 

US CDMO Operations Update

 

Five projects underway since opening of Abingdon Health USA Inc facilities in
April 2025

Phase two expansion plans for high throughput manufacturing capacity
progressing well

 

York, U.K.  1 September 2025: Abingdon Health plc (AIM: ABDX) a leading
international developer, manufacturer and regulatory services provider for
rapid diagnostic tests and med-tech, provides an update on the successful
establishment of contract development and manufacturing organisation ("CDMO")
activities at its Madison, Wisconsin facilities in the US with five new
development projects signed and underway.

 

Since April 2025, when its Madison facilities began operations, the Company
has worked with many customers and potential customers wanting US-based CDMO
services for lateral flow tests. Project details are confidential, but the
wide-ranging areas currently in progress via contract development projects
with US customers include:

 

·    Development of a duplex lateral flow to quantitatively measure the
concentrations of a pharmaceutical product and its metabolite.

·    Development of a lateral flow veterinary product for use initially in
canine samples.

·    Feasibility work with a leading US university to evaluate novel
nanoparticles for use in a lateral flow format.

·    Development of a lateral flow test for infectious disease initially
in bovine animals.

·    Development of a test for an infectious agent in animals and humans,
with a spin-out of leading US university.

 

All of these projects are being run from the Madison facility with support
from colleagues at the Company's UK facilities.

 

These contract wins underline the importance of Abingdon Health's expansion of
its CDMO offering in the US, extending its global reach to current and new
US-based clients. Abingdon Health's value proposition, which provides
customers with comprehensive support to take an "idea through to commercial
success", is resonating well in the USA.

 

 

Expansion of US facility

Abingdon Health also announces that the second phase of its US facility
expansion in Madison is underway with plans commenced for the installation of
high-throughput manufacturing to enable the seamless transition of projects
from development into manufacturing. The manufacturing equipment will mirror
Abingdon Health's UK operation to allow customers to manufacture under the
same operating conditions and quality management system in either the USA, the
UK, or both. This provides customers with unrivalled geographic optionality
during a period of tariff and supply chain uncertainty and provides US
customers with the confidence that products "developed in the USA" by the
Company's highly skilled CDMO team can also be "made in the USA".

 

 

Details of Abingdon Health's comprehensive CDMO capabilities can be found in
the brochure here:

https://www.abingdonhealth.com/wp-content/uploads/2025/06/Abingdon-Health-Group-Leaflet-JUN2025.pdf
(https://www.abingdonhealth.com/wp-content/uploads/2025/06/Abingdon-Health-Group-Leaflet-JUN2025.pdf)

 

Dr Chris Hand, Executive Chairman of Abingdon Health plc, commented:

"These contract awards validate our decision to expand our CDMO operations
into the USA and we anticipate further expansion in Madison, Wisconsin, as
projects and products move through the development cycle. It is pleasing to
see our US customers recognise the value of our comprehensive CDMO platform.
We deliver end-to-end diagnostic solutions from initial concept through to
market launch, and these contract wins illustrate strong confidence in our
approach from US-based clients".

 

Enquiries:

 

 Abingdon Health plc                           www.abingdonhealth.com/investors/ (http://www.abingdonhealth.com/investors/)
 Chris Hand, Executive Chairman                                            Via Walbrook PR
 Tom Hayes, CFO

 Zeus (Sole Broker and Nominated Adviser)                                    Tel: +44 (0)20 3829 5000
 Antonio Bossi / Jacob Walker (Corporate Finance)
 Fraser Marshall (Corporate Broking)

 Walbrook PR (Media & Investor Relations)      Tel: +44 (0)20 7933 8780 or abingdon@walbrookpr.com
                                               (mailto:abingdon@walbrookpr.com)
 Paul McManus / Alice Woodings                 Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654

 

 

About Abingdon Health plc

Abingdon Health Group is a leading med-tech contract service provider
offering its services to an international customer base.

 

The Group's CDMO
(https://www.abingdonhealth.com/services/your-complete-lateral-flow-partner/)
expertise offers lateral flow product development, regulatory support,
technology transfer and manufacturing services for customers looking to
develop new assays or transfer existing laboratory-based assays to a lateral
flow format.  Abingdon Health has the internal capabilities to take lateral
flow projects, in areas such as infectious disease and clinical testing,
including companion diagnostics, animal health and environmental testing, from
initial concept through to routine manufacturing; from "idea to commercial
success".  Abingdon Analytical Ltd offers performance evaluation for lateral
flow and other in vitro diagnostic assays from its Doncaster laboratory.

 

Abingdon's regulatory services companies, Compliance Solutions (Life
Sciences)
(https://urldefense.proofpoint.com/v2/url?u=https-3A__cslifesciences.com&d=DwMFAg&c=euGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM&r=b40MoFA_Q_fdsT77LXB5t3JFUZjlmpd2MVbmgvoBIOo&m=5rmPWmSeAYNtvo-wVGL_4V7p0wZ2qRPhbqDj6E6FHnhVakMVyzvk7wZG1jS6vI4P&s=PvbE1xuJgNrAaK0I9QSrYjO3acai4ITHsbheoH-Cavc&e=)
 and IVDeology
(https://urldefense.proofpoint.com/v2/url?u=https-3A__www.ivdeology.co.uk&d=DwMFAg&c=euGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM&r=b40MoFA_Q_fdsT77LXB5t3JFUZjlmpd2MVbmgvoBIOo&m=5rmPWmSeAYNtvo-wVGL_4V7p0wZ2qRPhbqDj6E6FHnhVakMVyzvk7wZG1jS6vI4P&s=mbRruUP_NEre93fFYpNkBweGVcmSCnXpjUyMQmUx1yI&e=)
, provide a broad range of regulatory services to the in vitro diagnostic and
wider medical device industry, to support customers in bringing products to
market across a range of territories including the USA, EU and the UK. Our
consultancy services range from design, implementation and maintenance of
quality management systems, preparation of technical files for regulatory
approvals, part-time and interim management support, auditing both internal
and external, management reviews and presentations, training and mentoring.

 

Founded in 2008, Abingdon Health is headquartered in York, England with
laboratories in Doncaster, England and laboratories and commercial offices in
Madison, Wisconsin, USA.

 

Abingdon Health's brochure
(https://www.abingdonhealth.com/wp-content/uploads/2025/06/Abingdon-Health-Group-Leaflet-JUN2025.pdf)
 outlines the comprehensive support the Group can now provide to its
international customers.  For more information visit: www.abingdonhealth.com
(https://urldefense.proofpoint.com/v2/url?u=http-3A__www.abingdonhealth.com_&d=DwMFAg&c=euGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM&r=b40MoFA_Q_fdsT77LXB5t3JFUZjlmpd2MVbmgvoBIOo&m=5rmPWmSeAYNtvo-wVGL_4V7p0wZ2qRPhbqDj6E6FHnhVakMVyzvk7wZG1jS6vI4P&s=Cd1Yy0EoU5vx33xedoTE3bCKbljgDOIRD8ol-bb59BM&e=)
.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDFLFSETEIAFIE